HeartBeam Inc. BEAT Archives - Page 5 of 11

MondayDec 16, 2024 9:10 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures FDA Clearance for Innovative Arrhythmia Assessment Device

HeartBeam (NASDAQ: BEAT) has received FDA 510(k) clearance for its groundbreaking HeartBeam system, a credit card-sized, cable-free ECG device designed for comprehensive arrhythmia assessment. The system enables patients to record high-fidelity heart signals from three directions during symptoms, with data transmitted to physicians for timely review and action. This milestone marks the first FDA-cleared device of its kind and lays the foundation for future advancements, including synthesized 12-lead ECGs, AI-driven arrhythmia detection, and heart attack risk assessment. HeartBeam aims to transform cardiac care by delivering actionable insights and predictive diagnostics for patients and physicians globally. To view the full press…

TuesdayNov 19, 2024 11:10 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Presents Positive Data for Groundbreaking Technology at AHA Conference

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, today announced the results from two studies evaluating its groundbreaking vector-based technology. According to the announcement, the data add to the body of evidence for HeartBeam’s key clinical indications, specifically arrhythmia and heart attack (myocardial infarction) detection, and showcase the technology’s pivotal role in advancing patient care. The studies were presented during the American Heart Association’s annual Scientific Sessions in Chicago, Nov. 16-18, 2024. “The data presentations at AHA are a testament to HeartBeam’s dedication to building a robust…

ThursdayOct 31, 2024 9:15 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q3 Earnings Call with Key Regulatory and Initiative Updates

HeartBeam (NASDAQ: BEAT), a medical technology company focused on enhancing cardiac care through advanced insights, will hold a conference call on November 7, 2024, at 4:30 p.m. ET to discuss third-quarter results and share updates on regulatory developments and ongoing projects. CEO Robert Eno, Founder and President Dr. Branislav Vajdic, and CFO Timothy Cruickshank will lead the call, which will include a Q&A session and a presentation accessible via the company’s investor relations page. A press release with detailed Q3 results will be released prior to the call. To view the full press release, visit https://ibn.fm/yqTng About HeartBeam Inc. HeartBeam…

ThursdayOct 24, 2024 9:00 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Wins 2024 Digital Health Hub Award for Innovation in Cardiac Care

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care, was recognized with the 2024 Digital Health Hub Rising Star award in the ‘Home Health Diagnostic’ category at the HLTH global healthcare conference. The award highlights HeartBeam’s innovative vector-based technology, which captures heart electrical signals in three dimensions to provide detailed cardiac insights. CEO Rob Eno emphasized the importance of timely care in cardiac health, praising the team’s efforts in developing a cable-free, credit card-sized ECG device, currently under FDA review, as a step towards personalized, AI-driven cardiac care. To view the full press release, visit https://ibn.fm/kUYI6 About…

TuesdaySep 10, 2024 11:11 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Appoints Industry Expert as New CFO

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has named a seasoned medtech leader as its new chief financial officer. According to the announcement, Timothy Cruickshank has accepted the role of chief financial officer, effective immediately; he succeeds Richard Brounstein, who announced his retirement. Cruickshank has a proven track record of strategic planning, financial stewardship and commercial success with a focus on growing businesses with disruptive technologies through authentic leadership, strategic focus, data-driven decisions, and strong risk management and governance. “Tim has an outstanding record of delivering results and creating…

ThursdayAug 01, 2024 10:44 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces Conference Call, Webcast to Discuss Q2 Results

HeartBeam(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has scheduled a conference call and webcast to discuss its second-quarter 2024 results. According to the announcement, the call is slated to begin at 4:30 p.m. ET on Aug. 14, 2024. HeartBeam executives, including Branislav Vajdic, CEO and founder; Robert Eno, president; and Ravi Malhotra, senior director and corporate controller, will host the call. During the call, the company leaders will discuss second-quarter results, provide regulatory updates, and review ongoing initiatives and anticipated 2024 milestones; the call will also include a question-and-answer period.…

MondayMay 20, 2024 2:08 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces Positive Study Data for Its AI Program

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced the results of a new study demonstrating that HeartBeam AI combined with vectorcardiography (“VCG”) outperformed an expert panel of heart rhythm cardiologists in detecting atrial flutter. Key findings from the analysis show that HeartBeam AI combined with VCG outperformed an expert panel reviewing single-lead ECGs and demonstrated a statistically significant 6% improvement in the detection of atrial flutter cases compared to an expert panel reviewing 12-lead ECGs. “The modern vectorcardiogram is nearly 100 years old, and yet we are cautiously…

TuesdayApr 09, 2024 3:35 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Presents Key Data in First-Ever Scientific Presentation of Proprietary HeartBeam AI

HeartBeam(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is presenting new data at the European Heart Rhythm Association (“EHRA”) Conference. According to the announcement, this is the first scientific presentation on the company’s deep learning algorithm: HeartBeam AI. The data demonstrates that applying the company’s artificial intelligence (“AI”) algorithms to vectorcardiography (“VCG”) showed considerably improved performance in the detection of atrial flutter over single-lead electrocardiograms (“ECGs”) and similar performance to 12-lead ECGs, the standard for diagnosing atrial flutter. The company noted that the data indicates an opportunity for a VCG-based algorithm…

ThursdayMar 21, 2024 12:33 pm

QualityStocksNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Financial Results, Corporate Highlights for Q4, FY 2023

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced its financial numbers and operational highlights for the fourth quarter and full year ended Dec. 31, 2023. According to the report, key achievements during the period included enrolling the first patients for a pivotal trial studying AIMIGo(TM) System for synthesizing a 12-lead ECG as well as clinical and regulatory progress made for the AIMIGo 3D VECG system. In addition, the company noted it had received two new patents during the period, covering HeartBeam’s proprietary technologies. “We have continued to make…

ThursdayMar 14, 2024 2:37 pm

QualityStocksNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Enrolls First Patients in Key Study Assessing Proprietary AIMIGo(TM) System

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has begun enrolling the first patients in its VALID-ECG pivotal study. According to the announcement, the first patients were enrolled at Atlanta Heart Specialists, a top cardiology physician practice in Atlanta, Georgia. HeartBeam anticipates the VALID-ECG study will form the basis of its planned FDA 510(k) submission. The study is designed to evaluate the performance of a 12-lead ECG synthesized from the credit-card-sized HeartBeam AIMIGo(TM) system compared to a standard hospital-based 12-lead ECG; the study will use both quantitative and qualitative methodologies…

Site Search

Company Search

Tag: HeartBeam Inc. BEAT